Browsing by Author "El Sony, A"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Essential Medicines at the National Level: The Global Asthma Network's Essential Asthma Medicines Survey 2014
    Bissell, K; Ellwood, P; Ellwood, E; Chiang, CY; Marks, GB; El Sony, A; Asher, I; Billo, N; Perrin, C; Asher, I; Billo, NE; Bissell, K; Chiang, CY; El Sony, A; Ellwood, P; García-Marcos, L; Mallol, J; Marks, GB; Pearce, N; Strachan, D; Priftanji, A; Boukari, R; Taright, S; Gómez, M; Baghdasaryan, A; Burgess, S; Marks, GB; Mattes, J; Tai, A; Riedler, J; Shpakou, A; Weyler, J; Lawin, H; de Abruzzese, JA; Domuz, S; Brandao, HV; Camargos, PAM; Fischer, GB; Menezes, AM; Neto, ACP; Rosário, N; Solé, D; Mustakov, TB; Birba, E; Ngahane, BHM; Tse, SM; Standring, P; Aguirre, V; Gil, MAC; Chen, YZ; Kan, X; Garcia, E; Niederbacher, J; Obel, BK; Soto-Quirós, ME; Banac, S; Yiallouros, P; Lochte, L; Barba, S; Bustos, C; El Falaki, M; Colorado, MF; Weihe, P; Lal, VA; Mäkelä, M; Annesi-Maesano, I; Raherison, C; Annesi-Maesano, I; Gotua, M; von Mutius, E; Addo-Yobo, EO; Akpinar-Elci, M; Lai, CKW; Novák, Z; Kabra, SK; Ilangho, RP; Pherwani, AV; Sharma, SK; Sukumaran, TU; Dalimunthe, W; Karimi, M; Masjedi, MR; Manning, P; Shohat, T; Forastiere, F; La Grutta, S; Petronio, MG; Piffer, S; Kahwa, E; Odajima, H; Abu-Ekteish, F; Amukoye, EI; Esamai, FO; Hong, SJ; Neziri-Ahmetaj, L; Momen, JA; Akkhavong, K; Svabe, V; Vlaski, E; Mortimer, K; Daud, M; Montefort, S; Navarro, BED; Gonzalez, CAJ; Merida-Palacio, JV; Paramo-Arroyo, RF; Munkhbayarlakh, S; Brunekreef, B; Annesi-Maesano, I; Asher, I; Currie, S; Douwes, J; Graham, D; Hancox, R; Moyes, C; Pattemore, P; Vis, K; Cordero, RMZ; Ayuk, A; Falade, AG; Garba, IB; Hammangabdo, A; Onyia, N; Pulu, M; Nystad, W; Al-Rawas, O; Yusuf, MO; Watson, BM; El Sharif, N; Cukier, G; Chiarella, P; Pagcatipunan, R; Brêborowicz, A; Lis, G; Morais-Almeida, M; Annesi-Maesano, I; Deleanu, D; Kamaltynova, E; Kondiurina, EG; Esera-Tulifau, L; Al-Ghamdi; Memish, ZA; Nahhas, MA; Yousef, A; Toure, NO; Visnjevac, D; Zivkovic, Z; Deen, GF; Goh, DYT; Masekala, R; Zar, HJ; Carvajal-Uruena, I; Garcia-Marcos, L; Diaz, CG; Murua, JK; Luna-Paredes, C; Morales-Suarez-Varela, M; Praena-Crespo, M; Kudagammana, ST; El Sony, A; Mohammad, Y; Guo, YL; Huang, JL; Lao-Araya, M; Teeratakulpisarn, J; Vichyanond, P; Anderson, S; Tidjani, O; Iosefa, T; Aho, G; Dookeeram, D; Hamzaoui, A; Yorgancioglu, A; Ituaso-Conway, N; Worodria, W; Fedortsiv, O; Mahboub, B; Mansur, AH; Kumar, H; Valentin-Rostan, M; Harrison, G; Fiocchi, A; Le, LTT; Wa Somwe, S; Manangazira, P
    Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013-2020 sets an 80% target for essential NCD medicines' availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013-2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system's capacity to address NCDs.
  • No Thumbnail Available
    Item
    Key messages and partnerships to raise awareness and improve outcomes for people with asthma and COPD in low- and middle-income countries
    Rylance, S; Bateman, ED; Boulet, L; Cohen, M; El Sony, A; Halpin, DMG; Khoo, EM; Marks, GB; Masekela, R; Mikkelsen, B; Mortimer, KJ; Muhwa, JC; Da Cunha, IN; Sajnic, A; Salvi, S; Slama, S; Winders, T; Yorgancioglu, A; Zar, HJ
  • No Thumbnail Available
    Item
    Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries
    Stolbrink, M; Chinouya, MJ; Jayasooriya, S; Nightingale, R; Evans-Hill, L; Allan, K; Allen, H; Balen, J; Beacon, T; Bissell, K; Chakaya, J; Chiang, CY; Cohen, M; Devereux, G; El Sony, A; Halpin, DMG; Hurst, JR; Kiprop, C; Lawson, A; Mace, C; Makhanu, A; Makokha, P; Masekela, R; Meme, H; Khoo, EM; Nantanda, R; Pasternak, S; Perrin, C; Reddel, H; Rylance, S; Schweikert, P; Were, C; Williams, S; Winders, T; Yorgancioglu, A; Marks, GB; Mortimer, K
    BACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low-and middle-income countries (LMICs), causing avoidable morbidity and mortality. The Inter-national Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022.METHODS: Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis.RESULTS: A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution.CONCLUSION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi -stake-holder, collaborative efforts.